Examkin

Question

Difficulty: MediumPreventive Care and Immunizations

A 4-year-old boy is brought to the pediatric clinic in late September for a well-child visit. He was diagnosed with moderate-to-severe Crohn disease 6 months ago. His current medications include infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, which has led to clinical remission and appropriate weight gain. He has no other medical conditions. His immunizations were up to date until his 18-month visit. He is now due for his routine preschool vaccinations, and the parents also request the seasonal influenza vaccine. His vital signs are temperature 36.8°C (98.2°F), heart rate 98/min, and respiratory rate 20/min. Physical examination is unremarkable.

Which of the following is the most appropriate immunization plan for this patient today?

  1. Administer DTaP, IPV, and inactivated influenza vaccines; defer MMR and varicella vaccinesAnswer
  2. B
    Administer DTaP, IPV, MMR, varicella, and inactivated influenza vaccines
  3. C
    Defer all vaccines until the patient has completed his course of infliximab
  4. D
    Administer MMR and varicella vaccines today; defer DTaP, IPV, and influenza vaccines to a later visit
  5. E
    Administer DTaP, IPV, MMR, varicella, and inactivated influenza vaccines, and prescribe prophylactic acyclovir

Answer

The most appropriate plan is to administer the inactivated vaccines (DTaP, IPV, and inactivated influenza) and to defer the live-attenuated vaccines (MMR and varicella).
The correct plan involves administering only the inactivated vaccines (DTaP, IPV, and inactivated influenza) and deferring the live-attenuated vaccines (MMR and varicella). This patient is receiving infliximab, a TNF-α inhibitor, which is a potent immunosuppressant. In severely immunocompromised patients, live-attenuated vaccines are strictly contraindicated because the vaccine strain viruses can undergo uncontrolled replication, leading to severe and potentially fatal disseminated disease. Conversely, inactivated vaccines cannot cause infectious disease and are safe to administer to immunocompromised individuals. They should be given on schedule to provide necessary protection, even though the overall immune response might be slightly blunted.

Step-by-Step Solution

1
Evaluate the patient's immune status based on his current medications.
The patient is taking infliximab, a biologic TNF-α inhibitor, which causes significant systemic immunosuppression.
Determining the immune status is the critical first step before administering any vaccines, as it dictates vaccine safety.
2
Determine the safety profile of the indicated preschool vaccines (DTaP, IPV, MMR, varicella, and seasonal influenza) in an immunocompromised host.
DTaP, IPV, and standard seasonal influenza vaccines are inactivated and safe. MMR and varicella are live-attenuated vaccines and are contraindicated.
Live-attenuated vaccines can cause uncontrolled viral replication and severe disease in immunocompromised patients, whereas inactivated vaccines pose no infectious risk.
3
Formulate the appropriate immunization plan for today's visit.
The plan must include the administration of the safe inactivated vaccines (DTaP, IPV, influenza) and the deferral of the contraindicated live vaccines (MMR, varicella).
This strategy maximizes the patient's protection against vaccine-preventable diseases without exposing him to the dangers of live vaccine administration.

Key Concept

In severely immunocompromised pediatric patients, such as those on TNF-α inhibitors, live-attenuated vaccines (e.g., MMR, varicella) are strictly contraindicated due to the risk of disseminated infection, whereas inactivated vaccines (e.g., DTaP, IPV) are safe and should be administered according to the routine schedule.
Estimated Time:1m 30s
Rate this question

Topics

Preventive Care and Immunizations

More questions from this topic